Home » Clinical Trials » Solid tumors » NCT05194735
NCT05194735

Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors

Study Summary

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors

Want to learn more about this trial?

Request More Info

Interventions

Neoantigen specific TCR-T cell drug productBIOLOGICAL
Phase I: Ascending dose, single Infusion of TCR+ Cells Phase II: Single infusion at the RP2D
Aldesleukin (IL-2)BIOLOGICAL
To support growth and activation of TCR-T cell drug product

Study Locations

FacilityCityStateCountry
MD Anderson Cancer CenterHoustonTexasUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026